Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded Double-Trouble Lipid Profile in Overweight/Obese

IntroductionWe evaluated the prevalence and control of dyslipidemia in a wide sample of patients referred to our ESH Hypertension Excellence Centre for high blood pressure (BP). Furthermore, we evaluated the role of adiposity on the serum lipid profile.MethodsObservational study on 1219 consecutive outpatients with valid ambulatory BP monitoring (ABPM) referred for high BP. Patients with body mass index (BMI)25kg/m(2) were defined as overweight/obese (OW/OB). Dyslipidemia and the control rates of low-density lipoprotein cholesterol (LDLc) were defined according to the 2016 ESC/EAS Guidelines.ResultsMean age: 56.513.7years. Male prevalence: 55.6%. OW/OB patients were 70.2%. The prevalence of dyslipidemia was 91.1%. Lipid-lowering drugs were taken by 23.1% of patients. Patients with controlled LDLc comprised 28.5%, while BP was controlled in 41.6% of patients. Only 12.4% of patients had both 24-h BP and LDLc controlled at the same time. The higher the cardiovascular (CV) risk was, the lower was the rate of LDLc control (p<0.001). Patients in secondary prevention had worse LDLc control than patients in primary prevention (OR 3.5 for uncontrolled LDLc, p<0.001). OW/OB showed a more atherogenic lipid profile, characterized by lower high-density lipoprotein cholesterol (HDLc) (p<0.001), higher non-HDLc (p=0.006), higher triglycerides (p<0.001), higher non-HDLc/HDLc (p<0.001) and higher (non-HDLc+non-LDLc) (p<0.001).ConclusionDyslipidemia is still too often neglected in hypertensives, especially in patients at higher CV risk. OW/OB hypertensives have a double-trouble atherogenic lipid pattern likely driven by adiposity. We encourage a comprehensive evaluation of the lipid profile in all hypertensives, especially if they are OW/OB, to correctly assess their CV risk and improve their management.FundingArticle processing charges funded by Servier SpA.